HEALTH TIPS.: Civica announces it is partnering with GeneSys Biologics, Blue Cross Blue Shield (BCBS) & others to market 3 insulins - glargine (cf. Lantus), lispro (cf. Humalog) and aspart (cf. Novolog) - with a recommended consumer price of $30. Civica will manufacture and obtain FDA approval.

Monday, 20 March 2023

Civica announces it is partnering with GeneSys Biologics, Blue Cross Blue Shield (BCBS) & others to market 3 insulins - glargine (cf. Lantus), lispro (cf. Humalog) and aspart (cf. Novolog) - with a recommended consumer price of $30. Civica will manufacture and obtain FDA approval.

Civica announces it is partnering with GeneSys Biologics, Blue Cross Blue Shield (BCBS) & others to market 3 insulins - glargine (cf. Lantus), lispro (cf. Humalog) and aspart (cf. Novolog) - with a recommended consumer price of $30. Civica will manufacture and obtain FDA approval.

submitted by /u/mikewinddale
[link] [comments]

from Health https://ift.tt/odPirgT
via IFTTT

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)